Enorama Pharma AB (publ) ("Enorama Pharma" or the "Company") today announces that the board of directors has decided to postpone the publication of the Company's 2025 year-end report until 11 March 2026. The previously announced date for publication of the year-end report was 17 February 2026.
The postponement of the publication of the year-end report is due to the Refuse-to-File decision from the U.S. Food and Drug Administration, as previously announced by Enorama Pharma on 2 February 2026, and the need to prepare a balance sheet for liquidation purposes.
CONTACT
Enorama Pharma AB (publ)
Bengt Jönsson, acting CEO
info@enorama.se
Strandvägen 7A, 114 51 Stockholm.
www.enorama.se
Enorama Pharma AB is listed on Nasdaq First North Growth Market.
The company's Certified Adviser is Tapper Partners AB, +46 (0)70 44 010 98, ca@tapperpartners.se.
ABOUT ENORAMA PHARMA
Enorama Pharma's vision is to be a leading global producer and supplier of consumer-friendly, oral nicotine products. The company intends to expand through product and brand development and by establishing strategically important collaborations. For more information, visit www.enorama.se.